Skip to main content

Fate Therapeutics Inc

FATE
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001434316

In the last 90 days, Fate Therapeutics Inc insiders filed 0 open-market purchases and 2 sales; 156 institutions reported holding it in 13F filings for Q2 2026, worth $193.2M in total; no superinvestor holds it.

Q3 2023 vs. Q2 2023

How the institutions holding Fate Therapeutics Inc changed between Q2 2023 and Q3 2023.

All holders in Q3 2023All holders in Q2 2023

13F holders of FATE: Q2 2023 compared with Q3 2023
MeasureQ2 2023Of which not filed for Q3 2023Q3 2023Change
Holders1882171−15
Shares109.1M1.11M95.5M−12.5M (−11.6%)
Value$519.6M$5.27M$202.9M−$311.4M (−60.5%)

2 institutions that held it in Q2 2023 haven't filed for Q3 2023 yet. Not filing isn't selling, so the changes leave them out.

New holders (20)

Institutions that held Fate Therapeutics Inc at the end of Q3 2023 but not at the end of Q2 2023.

Institutions new to FATE in Q3 2023
InstitutionSharesValue% of portfolio
AQR Capital Management LLC332,911$705.8K0.00%
PDT Partners, LLC138,814$294.3K0.04%
Putnam Investments LLC133,250$282.5K0.00%
SG Americas Securities, LLC73,642$156.0K0.00%
Verition Fund Management LLC52,654$111.6K0.00%
Aigen Investment Management, LP42,798$90.7K0.02%
Sciencast Management LP31,540$66.9K0.03%
Royce & Associates LP30,339$64.3K0.00%
Schonfeld Strategic Advisors LLC19,200$40.7K0.00%
Brevan Howard Capital Management LP17,337$36.8K0.01%
Herbst Group, LLC15,700$33.3K0.02%
JustInvest LLC14,354$30.4K0.00%
State of Wyoming14,259$30.2K0.01%
Sawtooth Solutions, LLC12,012$25.5K0.00%
Bleakley Financial Group, LLC12,012$25.5K0.00%
Fox Run Management, L.L.C.12,000$25.4K0.01%
National Bank of Canada12,000$22.9K0.00%
Victory Capital Management Inc10,182$21.6K0.00%
Group One Trading, L.P.6,289$13.3K0.00%
Glassman Wealth Services53$1120.00%

Sold out (35)

Institutions that held Fate Therapeutics Inc at the end of Q2 2023 and filed for Q3 2023 without it.

Not filed for Q3 2023 yet (2)

Institutions that held Fate Therapeutics Inc at the end of Q2 2023 and haven't filed a 13F for Q3 2023. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding FATE in Q2 2023 that haven't filed for Q3 2023
InstitutionShares, Q2 2023Value, Q2 2023
Pictet Asset Management SA1,090,260$5.19M
Tiaa, FSB17,592$83.7K